Journal
PEDIATRIC BLOOD & CANCER
Volume 68, Issue 11, Pages -Publisher
WILEY
DOI: 10.1002/pbc.29290
Keywords
autoimmune hepatitis; daratumumab; hematopoietic cell transplant
Categories
Ask authors/readers for more resources
This case report highlights the successful treatment of antibody-mediated autoimmune-like hepatitis post-HCT using daratumumab, suggesting its potential therapeutic value in other plasma cell-mediated disorders. Identification of immune-mediated injury mechanisms can allow for targeted therapy and reduce broad immune suppression.
Antibody-mediated autoimmune-like hepatitis is a rare and challenging occurrence after hematopoietic cell transplant (HCT). We present the case of a 16-year-old male patient with Ph+ ALL who underwent matched sibling donor HCT and developed autoimmune-like hepatitis after receiving ponatinib for post-HCT maintenance, evidenced by marked plasma cell infiltrate on liver biopsy. He was successfully treated with steroids and daratumumab, an anti-CD38-monoclonal antibody. The dramatic response in this patient warrants expanded investigation of daratumumab for plasma cell-mediated disorders post-HCT. It further highlights that identifying mechanisms of immune-mediated injury can allow for directed therapy and limit exposure to broad immune suppression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available